Gaviscon chewable mint tablets 24 pieces

Composition

active ingredients: 1 chewable tablet contains 250 mg of sodium alginate, 133.5 mg of sodium bicarbonate, 80 mg of calcium carbonate;

excipients: mannitol (E 421), macrogol 20,000, magnesium stearate, copovidone, acesulfame potassium, mint flavor, aspartame (E 951).

Release form

The tablet is round, flat with a bevel, almost white or cream in color, with small inclusions, with a mint aroma.

Pharmacodynamics. After oral administration, Gaviscon quickly interacts with gastric juice, forming a layer of alginic acid gel on its surface, which has a pH close to neutral, quickly and effectively covers the walls of the stomach (within 4 hours), preventing the occurrence of reflux. In severe cases, this layer can rise to the esophagus instead of the contents of the stomach and protect the walls of the esophagus. In addition, in vitro data have shown that the gel layer has a secondary effect and is able to retain bile and pepsin in its structure and thereby additionally protect the esophagus from these components of gastric juice.

Pharmacokinetics. The mechanism of action of the drug is physical and does not depend on the level of absorption into the systemic bloodstream.

Gaviscon mint tablets: treatment of symptoms of GERD, namely: heartburn; acid regurgitation; digestive disorders related to reflux, including during pregnancy.

Gaviscon mint tablets: contraindicated in case of hypersensitivity to any of the components of the drug.

Gaviscon mint tablets. Adults and children over 12 years of age should take 2-4 tablets orally after meals and before bedtime (up to 4 times a day). The tablets should be chewed. The drug should not be used for more than 7 days. If the symptoms of the disease persist or worsen during this period, the patient should consult a doctor to clarify the diagnosis and correct the treatment regimen.

The drug should not be used for more than 7 days. If the symptoms of the disease persist or worsen during this period, the patient should consult a doctor to clarify the diagnosis and correct the treatment regimen.

Special categories of patients

No dose adjustment is necessary in elderly patients.

Liver dysfunction: No dose adjustment is required.

Renal impairment: Use with caution in patients who need to follow a low-salt diet.

If there is no improvement after 7 days, the clinical picture should be reviewed. Patients on a low-salt diet, for example in renal failure or congestive heart failure, or when using drugs that can increase the level of potassium in the blood plasma, it should be taken into account that 10 ml of Gaviscon mint suspension contains 141 mg (6.2 mmol) of sodium, and 4 tablets of Gaviscon mint tablets and Gaviscon strawberry tablets contain 246 mg (10.6 mmol) of sodium, 10 ml of Gaviscon forte mint suspension contains 106 mg (4.6 mmol) of sodium and 78 mg (2.0 mmol) of potassium. It should also be noted that 10 ml of Gaviscon Mint Suspension suspension contains 160 mg (1.6 mmol) of calcium carbonate, 10 ml of Gaviscon Forte Mint Suspension contains 200 mg (2.0 mmol) of calcium carbonate, and 4 tablets of Gaviscon Mint Tablets and Gaviscon Strawberry Tablets contain 320 mg (3.2 mmol) of calcium carbonate, therefore the drug should be prescribed with caution to patients with hypercalcemia, nephrocalcinosis, and recurrent calcium-induced urolithiasis.

As Gaviscon mint tablets and Gaviscon strawberry tablets contain aspartame, they are not prescribed to patients with phenylketonuria. If there is no improvement within 7 days, you should consult a doctor.

Use during pregnancy and breastfeeding

Clinical studies involving more than 500 pregnant women, as well as a large amount of post-marketing experience, indicate the absence of toxic effects of the active substances on the newborn / infant, as well as their lack of ability to cause congenital malformations. The drug can be used during pregnancy if clinically necessary after consultation with a doctor.

Breastfeeding. Studies have shown no effects on newborns/infants breastfed by mothers who have used this drug. The drug can be used during breastfeeding after consulting a doctor.

Fertility: Preclinical studies have shown that alginate does not adversely affect the fertility or reproductive function of test animals or their offspring. Clinical data do not indicate an effect on human fertility.

Drivers

The drug does not affect the ability to drive vehicles and work with other mechanisms.

Children. The drug is contraindicated in children under 6 years of age. In children under 12 years of age, the drug can be used only as prescribed and under the supervision of a doctor. Gaviscon mint suspension is indicated for children over 6 years of age.

It occurs very rarely and manifests itself in the form of discomfort and a feeling of bloating.

The drug should be discontinued and symptomatic therapy should be administered.

Classified by frequency as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (≥1/10,000) and frequency unknown (cannot be estimated from the available data).

On the part of the immune system: very rarely – anaphylactic and anaphylactoid reactions, hypersensitivity reactions such as rash, urticaria.

Respiratory, thoracic and mediastinal disorders: very rarely – respiratory symptoms such as bronchospasm.

Gastrointestinal tract: frequency unknown – bloating, constipation.

Due to the presence of calcium carbonate, which acts as an antacid, at least 2 hours should elapse between taking Gaviscon and taking other medications, especially H2-histamine receptor blockers, tetracycline, digoxin, fluoroquinolone, iron salts, ketoconazole, neuroleptics, thyroxine, penicillamine, β-adrenoceptor blockers (atenolol, metoprolol, propranolol), corticosteroids, chloroquine, diphosphonates and estramustine.

Gaviscon mint tablets – at a temperature not exceeding 30 °C.